Canadian application, no grantCanada
Combinations of angiotensin converting enzyme, and carbonic anhydrase, inhibitors for treating glaucoma
CA 2005754 A1 · Owner: Merck & Co. Inc. · Inventors: Lotti, Victor J.; Baldwin, John J.
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Combinations of an angiotensin converting enzyme (ACE) inhibitor and a carbonic anhydrase (CA) inhibitor are synergistically effective in reducing intraocular pressure and thereby useful in the treatment and prevention of glaucoma.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 18, 1989. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 18, 2009.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 18, 2011.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledDecember 18, 1989
GrantedNo grant recorded
Term endedDecember 18, 2009
Patent numberCA 2005754 A1
Classification (IPC)A61K31/40 +1 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.